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诊断技术。在 MRI 成像中，获得的软组织成像分辨率高，利于诊断，但 MRI 的
设备昂贵，检查费用较高，常规扫描时间较长，这些缺点极大地限制了其发展和




































































Computed tomography (CT) is a non-invasive medical diagnostic technology, 
which is widely used in diagnostic process. It shows clearer imaging about the 
gastrointestinal, liver, cardiovascular, bone and tumor. But this technology also has 
some disadvangtages such as low resolution on brain tissue，soft tissue (muscles, 
tendons),the cartilage and other tissue. Magnetic resonance imaging (MRI) is also 
widely used for non-invasive medical diagnostic technologies. MRI imaging has a high 
resolution on soft tissue, but the MRI equipment is so expensive thus cause limitations 
on its application. CT Imaging together with MRI imaging techniques both have their 
advantages and disadvantages. Higher valuable medical diagnosis can be obtained by 
combining these two kinds of imaging techniques. 
Nowadays, commonly used clinical CT contrast agents are compounds of iodine, 
such as lipiodol, iohexol, etc. Lipiodol is an oily preparation of inorganic iodine 
combined with vegetable oil. With a high iodine content (30%-40%w/w), lipiodol 
became a high appliable contrast agent in CT Imaging. MRI imaging Contrast agent is 
commonly divided into ParaMagnetic, SuperParaMagnetism and iron magnetic. 
ParaMagnetic contrast agents such as grape gadopentetic acid amine are used to shorten 
the T1 relaxation time as well as enhancing the signal; superparamagnetic contrast 
agents and magnetic contrast agents such as iron oxide nanoparticles are used to shorten 
the T2 relaxation time. Iron oxide nanoparticles are widely used in MRI Imaging 
owning to their good biocompatibility and high sensitivity. 
Drug delivery system combines various good biocompatibility carriers with drugs 
so that they can control the drug release speed and appropriate concentration in living 
organisms, so as to achieve long-term effects. Carboxymethyl Chitosan has good 
biocompatibility, and can combinate with drugs with covalent bonds, which makes it a 
good drug delivery carrier.
    In this paper, we combinated carboxymethyl Chitosan together with acetylatied 















Meanwhile, anticancer drug doxorubicin hydrochloride was loaded on that magnetic 
nanoparticles by covalent modification.As a result, we obtained the modified magnetic 
nanoparticle for MRI, CT dual-model imaging, and drug sustainable delivery. Our Main 
contents and results include: 
(A) The preparation of carboxymethyl-Chitosan magnetic nanoparticles 
A modified solvothermal reaction method was applied to synthesize PEGylated 
magnetic particles, then the composite was modified with carboxymethy chitosan to 
increase its aqueous solubility, biocompatibility, loading capacity. Then detailed 
characterization and biocompatibility of the magnetic nanoparticles were performed. 
The result showed that the carboxymethyl Chitosan magnetic nanoparticles are about 
100nm in diameter, and with good magnetic, water solubility and biocompatibility, 
which make these carboxymethyl Chitosan magnetic nanoparticle a safe carrier. 
(B) Loading of Iodinated oil on carboxymethyl Chitosan magnetic nanoparticles 
TheCarboxymethyl Chitosan magnetic nanoparticles were loaded magnetic 
lipiodol and then measured its loading capacity of iodized oil as well as stability. The 
biocompatibility and CT/MRI image capacity were also evaluated. The result shows 
that the as prepared carboxymethyl Chitosan magnetic nanoparticles   were with good 
loading capacity, stability, biocompatibility and CT/MRI imaging capacity. Hence, the 
carboxymethyl Chitosan magnetic nanoparticles loaded with lipiodol are a promising 
contrast-enhanced dual-mode agent for CT and MRI. 
(C) Loading of doxorubicin hydrochloride on magnetic nanoparticles 
Through covalent modification we loaded magnetic nanoparticles with 
doxorubicin hydrochloride, which makes it valid foracting as CT/MRI dual-mode 
imaing agent as well as cancer treatment. Then we measured the drug-loaded 
nanoparticles drug delivery function, sustainable release capacity and Cytotoxicity. 
Results showed that the composite exhibited a good drug loading capacity and a 
sustained-release action. In vitro cytotoxicity test, it also confirmed that contained 
doxorubicin hydrochloride compound nanoparticles are toxic to tumor cell. 
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第一章  绪论 
  1 
第一章 绪论 
1.1 CT和 MRI成像系统 
1.1.1 X线的产生 










生转换。其中大约只有 1%的能量可以转换成 X 线，由 X 射线管的窗口发射呈
现，而剩下的 99%以上的能量会转换为热能，由散热设施散发损失[2]。 
1.1.2 CT 基本原理 
计算机体层成像（computed tomography，CT）技术由 Hounsfield 在 1969 年






纪 80 年代开始，随着物理学和影像学领域的发展，出现了一系列新型 CT 成像
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